Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing.

Compton P, Ling W, Chiang CN, Moody DE, Huber A, Ling D, Charuvastra C.

J Addict Med. 2007 Jun;1(2):88-95. doi: 10.1097/ADM.0b013e31806dcc3e.

PMID:
21768940
[PubMed]
2.

Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.

Compton P, Ling W, Moody D, Chiang N.

Drug Alcohol Depend. 2006 Mar 15;82(1):25-31. Epub 2005 Sep 6.

PMID:
16144748
[PubMed - indexed for MEDLINE]
3.

Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT.

Clin Pharmacokinet. 2004;43(5):329-40.

PMID:
15080765
[PubMed - indexed for MEDLINE]
4.

Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms.

Chawarski MC, Moody DE, Pakes J, O'Connor PG, Schottenfeld RS.

J Subst Abuse Treat. 2005 Dec;29(4):307-12.

PMID:
16311183
[PubMed - indexed for MEDLINE]
5.

Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

Chiang CN, Hawks RL.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S39-47. Review.

PMID:
12738349
[PubMed - indexed for MEDLINE]
6.

Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.

McAleer SD, Mills RJ, Polack T, Hussain T, Rolan PE, Gibbs AD, Mullins FG, Hussein Z.

Drug Alcohol Depend. 2003 Oct 24;72(1):75-83.

PMID:
14563545
[PubMed - indexed for MEDLINE]
7.

Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet.

Schuh KJ, Johanson CE.

Drug Alcohol Depend. 1999 Aug 2;56(1):55-60.

PMID:
10462093
[PubMed - indexed for MEDLINE]
8.

Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations.

Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, Mendelson JE.

J Clin Pharmacol. 1999 Jun;39(6):619-23.

PMID:
10354966
[PubMed - indexed for MEDLINE]
9.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
[PubMed - indexed for MEDLINE]
10.

Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.

Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE.

Drug Alcohol Depend. 2004 Apr 9;74(1):37-43.

PMID:
15072805
[PubMed - indexed for MEDLINE]
11.

A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.

Lintzeris N, Leung SY, Dunlop AJ, Larance B, White N, Rivas GR, Holland RM, Degenhardt L, Muhleisen P, Hurley M, Ali R.

Drug Alcohol Depend. 2013 Jul 1;131(1-2):119-26. doi: 10.1016/j.drugalcdep.2012.12.009. Epub 2013 Jan 12.

PMID:
23317685
[PubMed - indexed for MEDLINE]
12.

A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone).

Simojoki K, Vorma H, Alho H.

Subst Abuse Treat Prev Policy. 2008 Jun 17;3:16. doi: 10.1186/1747-597X-3-16.

PMID:
18559110
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.

Ciraulo DA, Hitzemann RJ, Somoza E, Knapp CM, Rotrosen J, Sarid-Segal O, Ciraulo AM, Greenblatt DJ, Chiang CN.

J Clin Pharmacol. 2006 Feb;46(2):179-92.

PMID:
16432270
[PubMed - indexed for MEDLINE]
14.

A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.

Bell J, Byron G, Gibson A, Morris A.

Drug Alcohol Rev. 2004 Sep;23(3):311-7.

PMID:
15370011
[PubMed - indexed for MEDLINE]
15.

Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers.

Fischer A, Jönsson M, Hjelmström P.

Drug Dev Ind Pharm. 2013 Oct 7. [Epub ahead of print]

PMID:
24099551
[PubMed - as supplied by publisher]
16.

Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Amass L, Kamien JB, Mikulich SK.

Drug Alcohol Depend. 2000 Feb 1;58(1-2):143-52.

PMID:
10669065
[PubMed - indexed for MEDLINE]
17.

Buprenorphine: how to use it right.

Johnson RE, Strain EC, Amass L.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S59-77. Review.

PMID:
12738351
[PubMed - indexed for MEDLINE]
18.

Plasma concentrations of buprenorphine 24 to 72 hours after dosing.

Chawarski MC, Schottenfeld RS, O'Connor PG, Pakes J.

Drug Alcohol Depend. 1999 Jun 1;55(1-2):157-63.

PMID:
10402160
[PubMed - indexed for MEDLINE]
19.

Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.

Kovarik JM, Noe A, Berthier S, McMahon L, Langholff WK, Marion AS, Hoyer PF, Ettenger R, Rordorf C.

J Clin Pharmacol. 2003 Feb;43(2):141-7.

PMID:
12616666
[PubMed - indexed for MEDLINE]
20.

Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.

Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, Cone EJ.

Addiction. 1998 Apr;93(4):549-59.

PMID:
9684393
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk